Teleflex to Showcase its Interventional Portfolio Highlighting the MANTA® Vascular Closure Device and the Langston® Dual Lu...
Teleflex Incorporated (NYSE: TFX), a leading global provider of
medical technologies, will showcase its Interventional product
portfolio including the MANTA® Vascular Closure Device and
Langston® Dual Lumen Catheters at the PCR London Valves being held
in London, United Kingdom on November, 17th – 19th, 2019.
Teleflex offers a growing portfolio of
specialty-focused solutions designed to improve the health and
quality of people’s lives around the world. Our portfolio is known
for innovative devices that simplify complex procedures and
overcome common procedural challenges. Used by Interventionalists
worldwide, our device-based solutions include the MANTA® Device and
the Langston® Dual Lumen Catheters.
The CE Marked MANTA® Vascular Closure Device is
the first commercially available biomechanical vascular closure
device specifically designed for closure of large bore femoral
arteriotomies following procedures utilizing devices or sheaths
ranging in size from 10F to 18F (with maximum outer diameters up to
25F). In the SAFE MANTA® IDE Clinical Trial, the IDE-defined major
complication rate occurred in 5.3% of patients and VARC-2 major
vascular complication rate occurred in 4.2% of cases. This VARC-2
rate is lower than published rates for suture-mediated closure.
Langston® Dual Lumen Catheters are angiographic
catheters with a two-lumen coaxial design which enables
simultaneous pressure measurements across the aortic valve. The
precise pressure obtained using Langston® Pigtail catheters help
clinicians compute the pressure gradient and subsequently the
effective orifice area.
Clinicians worldwide rely on the quality and proven clinical
utility of our interventional portfolio.
About Teleflex IncorporatedTeleflex is a global
provider of medical technologies designed to improve the health and
quality of people’s lives. We apply purpose driven innovation – a
relentless pursuit of identifying unmet clinical needs – to benefit
patients and healthcare providers. Our portfolio is diverse, with
solutions in the fields of vascular access, interventional
cardiology and radiology, anesthesia, emergency medicine, surgical,
urology and respiratory care. Teleflex employees worldwide are
united in the understanding that what we do every day makes a
difference. For more information, please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®,
Pilling®, Rüsch®, UroLift®, and Weck® – trusted brands united by a
common sense of purpose.
Forward-Looking StatementsAny statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which
may cause actual results or company actions to differ materially
from what is expressed or implied by these statements. These risks
and uncertainties are identified and described in more detail in
our filings with the Securities and Exchange Commission, including
our Annual Report on Form 10-K.
Teleflex, the Teleflex logo, Arrow, Deknatel, Hudson RCI,
Langston, LMA, MANTA, Pilling, Rüsch, UroLift, and Weck are
trademarks or registered trademarks of Teleflex Incorporated or its
affiliates, in the U.S. and/or other countries. countries © 2019
Teleflex Incorporated. All rights reserved. MCI-2019-0836.
References: 1. Wood D, et al. Pivotal Clinical
Study to Evaluate the Safety and Effectiveness of the MANTA®
Percutaneous Vascular Closure Device: The SAFE MANTA® Study.
Circulation: Cardiovascular Interventions. 2019 July. Vol 12, Issue
7.a. Major complications defined as composite of i) vascular injury
requiring surgical repair/stent-graft; ii) bleeding
requiring transfusion; iii) lower extremity ischemia requiring
surgical repair/additional percutaneous intervention; iv) nerve
injury (permanent or requiring surgical repair); and v) infection
requiring IV antibiotics and/or extended hospitalizationStudy
sponsored by Teleflex Incorporated or its affiliates.2. Généreux P,
et al. Vascular complications after transcatheter aortic valve
replacement. J Am Coll Cardiol. 2012 Sept 18;60(12):1043-1052.3.
Lauten A, et al. Percutaneous left-ventricular support with the
Impella 2.5®-assist device in acute cardiogenic shock: results of
the Impella-EUROSHOCK-registry. Circ Heart Fail. 2013
Jan;6(1):23-30.4. Data on file at Teleflex.
Source: Teleflex IncorporatedJake
ElguiczeTreasurer and Vice President, Investor
Historical Stock Chart
From Jul 2020 to Aug 2020
Historical Stock Chart
From Aug 2019 to Aug 2020